Tumor necrosis factor-alpha and its receptors in epithelial ovarian cancer.

Abstract

Abstract:The aim of the present study was to characterize the expression pattern of tumor necrosis factor (TNF)-α and its receptors (TNF-Rs) in the epithelial ovarian cancer (EOC) and compare these results with the outcome of 126 patients. Presence of TNF-α, TNFR-1 and TNFR-2 were studied by Western blotting and immunohistochemistry. The proportion of samples positive for TNF-α and TNF-R2 was higher in epithelial ovarian cancer patients than in benign ovarian diseases (p<0.001 and p=0.016, respectively). Immunostaining intensity of TNF-R2 were correlated with tumor stage (p<0.001) and with reduced mean survival time (MST) (p=0.002). The results of the present study suggested that tissue expression of TNF-R2 in epithelial ovarian cancer was correlated with the highest risk of cancer progression. Thus, the clinical value of activated TNF system in epithelial ovarian cancer needs to be further investigated.Keywords: tumor necrosis factor-α (TNF-α); tumor necrosis factor receptor 1 (TNF-R1); tumor necrosis factor receptor 2 (TNF-R2); epithelial ovarian cancer (EOC) Correspondence: B. Dobrzycka,

Interaction between TNFR1 and TNFR2 dominates the clinicopathologic features of human hypopharyneal carcinoma

“…In human cancers, the expression of TNFRs implicates different aspects of TNFR functions. In epithelial ovarian cancer, the expression of TNFR2 was higher in epithelial ovarian cancer patients than in benign ovarian diseases; the expression intensity of TNFR2 was correlated with tumor stage and with reduced mean survival time [20]. In diffuse large B cell lymphoma, Nakayama found that TNFR1-positive expression was associated with a poorer overall survival.…”

Immunology and Immunotherapy of Ovarian Cancer

“…Similarly, increased TNF-α concentrations were observed in cancer tissues and ascites [ 225 ]. Cancer patients were also characterized by overexpression of receptor TNF-R2, which was further correlated with tumor stage and patient prognosis [ 226 ]. TNF-α is produced by tumor cells, and studies devoted to EOC indicated its multidirectional activity, as an autocrine stimulator of tumor progression and neovascularization as well as a downregulator of Tregs and enhancer of the host immunity against tumor [ 54 , 227 -229 ].…”

Cancer Immunoediting: Elimination, Equilibrium, and Immune Escape in Solid Tumors

“…Increased TNF-α concentrations have been observed in ovarian cancer patients in serum and cyst fluid, as well as in cancer tissues and ascites [310,311]. Cancer patients have also been characterized by overexpression of receptor TNF-R2, which was further correlated with tumor stage and patient prognosis [312]. TNF-α expressed on tumor cells orchestrates the paracrine "TNF network", and together with IL-6 and CXCL12 regulates tumor growth [313].…”